Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Equity Ratio (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Equity Ratio for 10 consecutive years, with 0.29 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 422.83% to 0.29 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.29 through Dec 2025, up 422.83% year-over-year, with the annual reading at 0.29 for FY2025, 422.83% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.29 at Rhythm Pharmaceuticals, down from 0.29 in the prior quarter.
  • The five-year high for Equity Ratio was 0.91 in Q3 2021, with the low at 0.03 in Q2 2025.
  • Average Equity Ratio over 5 years is 0.49, with a median of 0.57 recorded in 2023.
  • Peak annual rise in Equity Ratio hit 851.8% in 2025, while the deepest fall reached 131.01% in 2025.
  • Over 5 years, Equity Ratio stood at 0.86 in 2021, then dropped by 19.88% to 0.69 in 2022, then fell by 26.16% to 0.51 in 2023, then tumbled by 89.14% to 0.06 in 2024, then skyrocketed by 422.83% to 0.29 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.29, 0.29, and 0.03 for Q4 2025, Q3 2025, and Q2 2025 respectively.